Vaxcyte AI Stock Analysis
Want to see PCVX full AI Analyst Report?
Vaxcyte (PCVX) AI Stock Analysis
Vaxcyte
(NASDAQ:PCVX)
Overall score reflects weak fundamentals driven by pre-revenue status and accelerating losses/cash burn, partially offset by a strong capital base. Technicals are supportive with the stock above key moving averages and moderate momentum. Corporate events add upside via positive Phase 3 data and fresh financing, while valuation remains challenged given negative earnings and no dividend support.
Vaxcyte (PCVX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.16M
- Price to Earnings (P/E)
- -8.5
- Beta (1Y)
- 2.06
- Revenue Growth
- ―
- EPS Growth
- -65.42%
- Country
- US
- Employees
- 507
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Vaxcyte Business Overview & Revenue Model
Company Description
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candid...
Vaxcyte Earnings Call Summary
The call presents a strongly positive operational and clinical momentum story: robust balance sheet extended by a ~$600M financing, completion of a commercial-scale manufacturing facility on time and on budget, initiation of three pivotal/Phase III adult OPUS trials with expected top-line readouts over the next 18 months, completed infant enrollment (900 infants), and resumption of the Group A Strep program. Offsetting risks are mostly predictable near-term impacts from materially higher R&D and manufacturing expenses in 2026, serotype-level regulatory uncertainties (and the idiosyncratic challenge of serotype 3), and a competitive landscape with other PCV developers. Overall, the highlights—particularly cash runway, manufacturing completion, and late-stage clinical progress—materially outweigh the lowlights, which are manageable programmatic and financial execution risks.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
The company guided to a busy, capital-intensive 2026–2027 cadence: as of 12/31/2025 Vaxcyte had $2.4 billion in cash, then raised ~ $600.2 million net proceeds and said this funding provides runway to at least the end of 2028; it expects total expenses—particularly R&D—to increase meaningfully in 2026 while capitalized costs trend down. Key clinical and timing metrics: the OPUS Phase III program will enroll ~6,000 adults (≈3,400 receiving VAX‑31) with OPUS‑1 top‑line safety/tolerability/immunogenicity data expected in Q4 2026 and OPUS‑2 and OPUS‑3 readouts in H1 2027; the VAX‑31 infant Phase II optimized cohort enrollment is complete (900 infants dosed) with primary 3‑dose and booster data due by end H1 2027; VAX‑A1 Phase I in adults is planned to start in 2026. Product and regulatory metrics highlighted include a 31‑valent design with 10–11 incremental serotypes versus comparators, analytical plans that allow noninferiority against one comparator for the 10 shared serotypes, roughly 10 serotypes comparing head‑to‑head with Prevnar‑20 and 8 exclusive serotypes versus Capvaxive, and the expectation to meet conventional safety exposure norms (>3,000 subjects); manufacturing progress includes a dedicated large‑scale facility completed on time/on budget, a North Carolina fill‑finish build‑out as part of up to $1 billion U.S. manufacturing investment, and ongoing plans for a manufacturing consistency study.
Vaxcyte Financial Statement Overview
Summary
Financial profile is weak due to zero revenue and sharply widening losses (net loss roughly -$1.15B TTM) alongside heavy cash burn (free cash flow about -$1.28B TTM). The key offset is a comparatively solid balance sheet with sizable equity (~$2.49B TTM) and modest debt (~$222M TTM), but funding dependence and dilution risk remain high.
Income Statement
12Very NegativeBalance Sheet
68PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -865.00K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -1.13B | -741.77M | -448.08M | -392.10M | -214.03M | -96.61M |
| Net Income | -1.15B | -766.63M | -463.93M | -402.27M | -223.49M | -100.08M |
Balance Sheet | ||||||
| Total Assets | 2.99B | 3.00B | 3.51B | 1.41B | 1.01B | 324.34M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.56B | 1.75B | 1.08B | 931.38M | 245.97M |
| Total Debt | 221.84M | 117.48M | 71.11M | 29.22M | 17.94M | 16.78M |
| Total Liabilities | 499.92M | 317.21M | 205.50M | 167.45M | 52.56M | 40.32M |
| Stockholders Equity | 2.49B | 2.69B | 3.31B | 1.24B | 953.61M | 284.02M |
Cash Flow | ||||||
| Free Cash Flow | -1.28B | -669.29M | -475.05M | -364.67M | -176.44M | -127.95M |
| Operating Cash Flow | -1.24B | -655.58M | -452.63M | -296.79M | -170.60M | -121.39M |
| Investing Cash Flow | -33.20M | 437.35M | -2.01B | -773.31M | 74.58M | -212.31M |
| Financing Cash Flow | 1.21B | 2.01M | 2.45B | 639.81M | 861.55M | 17.80M |
Vaxcyte Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCVX, the sentiment is Positive. The current price of 68.62 is above the 20-day moving average (MA) of 63.37, above the 50-day MA of 62.13, and above the 200-day MA of 57.58, indicating a bullish trend. The MACD of 0.99 indicates Negative momentum. The RSI at 59.53 is Neutral, neither overbought nor oversold. The STOCH value of 91.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCVX.
Vaxcyte Risk Analysis
Vaxcyte disclosed 71 risk factors in its most recent earnings report. Vaxcyte reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVaxcyte Peers Comparison
Overall Rating
TWST73Outperform
VIR56Neutral- PCVX56Neutral
MRVI48Neutral
NVAX47Neutral
IBRX46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TWST | 73Outperform | $8.70B | -55.22 | -29.89% | ― | 19.19% | -53.86% |
| VIR | 56Neutral | $2.25B | -10.50 | -21.38% | ― | 1695.96% | 65.40% |
| PCVX | 56Neutral | $10.50B | -8.50 | -42.04% | ― | ― | -65.42% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MRVI | 48Neutral | $2.04B | -17.28 | -31.86% | ― | 10.77% | 46.91% |
| NVAX | 47Neutral | $1.68B | -21.70 | 45.13% | ― | -61.33% | -121.87% |
| IBRX | 46Neutral | $7.18B | -6.22 | 124.59% | ― | 121.15% | -162.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PCVX | Vaxcyte, Inc. | 68.62 | 23.07 | 50.65% | |
| NVAX | Novavax | 9.98 | 2.92 | 41.36% | |
| IBRX | Immunitybio Inc | 6.67 | 4.67 | 233.50% | |
| TWST | Twist Bioscience | 122.59 | 92.69 | 310.00% | |
| VIR | Vir Biotechnology, Inc. | 13.13 | 7.66 | 140.04% | |
| MRVI | Maravai Lifesciences Holdings, Inc. | 7.70 | 4.45 | 136.92% |
Vaxcyte Corporate Events
Vaxcyte Bolsters Capital Structure with New Offerings
PositiveOn October 9, 2026, Vaxcyte closed concurrent equity and convertible debt offerings, issuing $575 million of 1.50% Convertible Senior Notes due 2032 and selling 8,984,375 shares of common stock and 400,000 pre-funded warrants. The transactions, inclu...
Vaxcyte Announces Positive Phase 3 Results for VAX-31
PositiveOn October 5, 2026, Vaxcyte reported positive topline data from its pivotal OPUS-1 Phase 3 trial of VAX-31 in adults, showing the 31-valent pneumococcal conjugate vaccine met all prespecified primary immunogenicity and safety endpoints compared with...
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline
PositiveOn August 31, 2026, Vaxcyte appointed David McAvoy as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary, while Mikhail Eydelman continues as Senior Vice President and General Counsel. On September 3, 2026, the company named former...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026